OnCo
peoplePerson

Amit M. Oza

Amit Oza is a gynaecologic oncologist who led early olaparib and niraparib studies in ovarian cancer.

Led phase 2 trials establishing PARP inhibition in BRCA-mutant and platinum-sensitive ovarian cancer and heads medical oncology at Princess Margaret.

Role
Head, Division of Medical Oncology and Hematology; Director, Cancer Clinical Research Unit
Specialisms
Ovarian cancerPARP inhibitorsGynaecologic trials

Papers

1top
TitleJournalYear
Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trialLancet Oncology2015

Key papers

1top
rctNew England Journal of Medicine 2018changed practice
SOLO-1: two years of olaparib maintenance after first-line chemotherapy for BRCA-mutated ovarian cancer

Every woman diagnosed with advanced high-grade ovarian cancer should be tested for BRCA mutations at diagnosis, because those who carry one should receive two years of olaparib after chemotherapy, which greatly extends the time in remission and improves long-term survival. The plateau in the survival curves suggests some patients are cured by this approach. Toxicity is mostly anaemia, fatigue and nausea, and the two-year limit appears sufficient.

Connected

7top

Pages like this

not linked directly; found by shared links

cancers

2
Endometrial cancerOvarian cancer

targets

1
PARP

drugs

2
ApprovedSmall-molecule PARP inhibitor
Niraparib · Zejula
ApprovedSmall-molecule PARP inhibitor
Olaparib · Lynparza

institutions

1
Princess Margaret Cancer Centre

key papers

1
SOLO-1: two years of olaparib maintenance after first-line chemotherapy for BRCA-mutated ovarian cancer